News

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

March 4, 2020March 4, 2020

Early Onset Dementia, AD Diagnoses Rose 200% in 4 Years, BCBSA Report Finds

News

The number of commercially insured U.S. residents diagnosed with early onset dementia and Alzheimer’s disease (AD) rose by 200% from 2013 to 2017, and the average age of a ... Read more

March 3, 2020March 3, 2020

Temple Scientist Awarded $500K Grant to Advance Alzheimer’s Drug Discovery

News

A Temple University researcher has been awarded a $500,000 two-year grant to develop a treatment that targets chronic brain inflammation and other disease characteristics in Alzheimer’s. Silvia Fossati, associate ... Read more

February 28, 2020February 28, 2020

Cognitive Difficulties Can Predict Neurodegeneration, Study Finds

News

Researchers have found that amyloid, the protein that forms toxic aggregates, or clumps in the brain and is thought to be involved in the onset of Alzheimer’s disease (AD), ... Read more

February 26, 2020February 26, 2020

DNA from Bacteria in Brain May Promote Tau Clumping, Study Suggests

News

DNA from various species of bacteria, some of which — like E. coli — have been identified in the brains of Alzheimer’s patients, can cause the tau protein to fold ... Read more

February 25, 2020February 25, 2020

New Carbon Nanotube Sensor Ably Spots Alzheimer’s via Proteins in Blood, Study Reports

News

A new biosensor using neatly aligned carbon nanotubes may bring scientists one step closer to a blood test for the early detection of Alzheimer’s disease. The nanotubes were able to ... Read more

February 24, 2020February 24, 2020

Phase 2 Trial into Potential Oral Alzheimer’s Treatment Safe to Continue, Independent Board Says

News

A Phase 2 clinical trial testing Annovis Bio‘s oral therapy ANV401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review ... Read more

February 21, 2020February 21, 2020

Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds

News

Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in ... Read more

February 19, 2020February 19, 2020

Biogen to Start Re-dosing Aducanumab in Alzheimer’s Patients From Halted Trials

News

Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted ... Read more

February 18, 2020February 18, 2020

Number of Dementia Cases Likely to Double by 2050 as Europe Ages, Report Says

News

The number of people with dementia in 37 countries in and near Europe is likely to double to 18.8 million by 2050, according to Alzheimer Europe. That’s more than ... Read more

Pin It on Pinterest